NeoGenomics Reports Q2 Revenue of $181.3mln, Down from Estimates, Net Loss of $45.1mln.

• Pomerantz LLP investigating NeoGenomics securities fraud claims • Investors advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 • NeoGenomics reports Q2 2025 revenue of $181.3 million, below consensus estimates • Net loss of $45.1 million and reduced 2025 revenue forecast to $720-$726 million • Adjusted EBITDA projection lowered to $41-$45 million

New York, Aug. 2, 2025 — NeoGenomics (NASDAQ: NEO), a leading oncology diagnostics company, is facing a class action lawsuit alleging securities fraud. The lawsuit, filed by Pomerantz LLP, claims that the company and certain of its officers and/or directors engaged in unlawful business practices. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 to inquire about their rights [1].

NeoGenomics reported its Q2 2025 earnings on July 29, 2025, revealing a 10.2% year-on-year increase in revenue to $181.3 million, which fell short of analysts' expectations of $182.9 million. The company's full-year revenue guidance was reduced to $723 million at the midpoint, down 2.9% from previous estimates. The company also reported a net loss of $45.1 million and an adjusted EBITDA projection of $41-$45 million, down from prior estimates [2].

The company attributed its underperformance to persistent pharma sector headwinds, a delayed launch of its PanTracer liquid biopsy product, and ongoing product mix challenges. Despite these headwinds, NeoGenomics highlighted solid growth in its core clinical business and continued share gains in high-value testing segments. The company expects the second half of the year to be shaped by the commercial rollout of new products, continued clinical market share gains, and a cautious outlook for its pharma services segment [2].

Investors should closely monitor the outcome of the class action lawsuit and the company's ability to execute on its strategic initiatives. The company's stock price fell to $5.84 after the earnings report, down from $6.48 before the announcement [2].

References:
[1] https://www.morningstar.com/news/globe-newswire/9510056/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-novo-nordisk-as-of-class-action-lawsuit-and-upcoming-deadlines-nvo
[2] https://finance.yahoo.com/news/neo-q2-deep-dive-guidance-045656424.html